Stock Upgrades Today Show Top Picks

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  11 Dec 2025
 

•   ABBV  
   
  +0.71%
•   ALAB  
   
  +0.41%
•   ALB  
   
  +0.20%
•   BNTX  
   
  +0.02%
•   FICO  
   
  -0.06%

$ABBV HSBC upgraded AbbVie to Buy, raising its price target to $265. The firm highlighted AbbVie solid fundamentals and pipeline strength, cementing its place among the top long-term plays in the pharma space. With ongoing clinical successes and steady dividend growth, ABBV is positioned to offer both stability and upside potential.

$ALAB Astera Labs received a price target boost to $195 from H.C. Wainwright as AI infrastructure demand accelerates. Analysts see ALAB as a key player poised to benefit from surging AI adoption, and the upgraded rating underscores Wall Street confidence in its growth trajectory.

$ALB UBS upgraded Albemarle to Buy from Neutral, lifting its price target to $185 from $107. The move reflects expectations of a lithium deficit driving strong demand for energy storage solutions. With the global push toward electrification, ALB is strategically positioned for long-term growth.

$BNTX BioNTech SE remains a Buy according to Clear Street, buoyed by promising lung cancer treatment prospects. The biotech continues to innovate with experimental therapies, and this endorsement highlights the potential to deliver meaningful breakthroughs in oncology.

$CL Colgate-Palmolive was upgraded to Outperform by RBC, maintaining a price target of $88. Analysts cited consistent long-term growth prospects, despite recent category headwinds, reflecting confidence in CL resilience and ability to navigate evolving consumer trends.

$FICO Fair Isaac Corporation continues to impress with strong fundamentals and guidance that suggests it should outperform expectations. The Buy rating reflects confidence in its analytics-driven revenue growth and market leadership in credit scoring solutions.

$HLNE Hamilton Lane saw coverage resumed at UBS with a Buy rating, emphasizing its potential in wealth strategy and alternative investments. Analysts highlight the ability to capitalize on expanding private markets and deliver attractive long-term returns.

$JNJ Guggenheim maintains a Buy on Johnson & Johnson, raising its price target to $227 from $206. The upgrade underscores confidence in JNJ diversified healthcare portfolio and continued innovation across pharmaceuticals, medical devices, and consumer health.

$MRVL Marvell Technology retains its Buy rating from Stifel, supported by strong ASIC leadership and AI chip market positioning. Analysts dismissed market rumors as baseless, reinforcing credibility as a key AI infrastructure play.

$MU Micron Technology was initiated as a Buy by HSBC with a $330 price target and reaffirmed by UBS at $275 ahead of earnings. Analysts cite robust AI memory demand and tech leadership, highlighting MU ability to outperform peers in a rapidly expanding AI-driven semiconductor market.

$ORCL Oracle received a notable upgrade despite recent earnings disappointment. Analysts remain confident in its cloud and enterprise software growth, emphasizing ORCL long-term resilience and strategic positioning in enterprise IT solutions.

$OSCR Piper Sandler upgraded Oscar Health to Overweight with a $25 price target, citing market share gains and profitability growth. Analysts highlighted Oscar innovative insurance model and favorable benefit design strategy as key drivers for near-term upside.

$RARE Ultragenyx Pharmaceutical retains a Buy rating from Citi, supported by biotech innovation and a $103 price target. The stock remains compelling for those seeking exposure to high-potential biotech treatments with strong Wall Street backing.

$SNPS Synopsys maintains its Buy rating at Stifel despite mixed results, reflecting confidence in its long-term growth trajectory driven by semiconductor design automation and software tools.

$U Unity Software was upgraded by Piper Sandler, benefiting from accelerating mobile advertising growth. Analysts see U as well-positioned to capture expanding monetization opportunities across gaming and interactive content.

$UNFI United Natural Foods outlined a multi-year growth plan with stronger cash flow and operational upgrades through 2028. Analysts are positive on UNFI strategic initiatives aimed at sustainable growth and market share expansion.

$V Visa was upgraded to Buy, supported by upside potential and emerging stablecoin prospects. Analysts note the strong market position and innovative payment solutions as catalysts for continued revenue growth.

$VKTX Viking Therapeutics remains a Strong Buy according to H.C. Wainwright, reflecting its rapid enrollment completion in a Phase 3 obesity study. Analysts see VKTX as a high-potential biotech stock with meaningful near-term catalysts.

$VZ Verizon continues to innovate in stadium and event technology, enhancing fan experiences with Wi-Fi 6E upgrades. Analysts view VZ as a solid Buy given its network capabilities and strategic growth in enterprise and consumer services.

View All Headlines